Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1Breast 1

Conditions

Musculoskeletal Pain 1Drug-Related Side Effects and Adverse Reactions 1Breast Neoplasms 1

Interventions

Cyclophosphamide 171Docetaxel 164Paclitaxel 160Trastuzumab 152Capecitabine 130Tamoxifen 119Letrozole 105Epirubicin 93Doxorubicin 83Anastrozole 83exemestane 77Fulvestrant 75Carboplatin 64Fluorouracil 63Radiotherapy 61pertuzumab 59Gemcitabine 55Vinorelbine 43Goserelin 39eribulin 36130-nm albumin-bound paclitaxel 36palbociclib 32Bevacizumab 32ribociclib 30Zoledronic Acid 29Lapatinib 29Methotrexate 28Drug Therapy 28Chemotherapy, Adjuvant 28Ado-Trastuzumab Emtansine 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Furosemide × Breast × Clear all
NCT06407401 2024-11-05

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Not yet recruiting
399 enrolled
Breast

Breast Neoplasms, Musculoskeletal Pain, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡